Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
58 Mrsa Trials
Power is an online platform that helps thousands of Mrsa patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
mRNA-1083 Vaccine for Influenza and COVID-19
Cincinnati, OhioThe purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 64
Sex:All
1300 Participants Needed
Sural Nerve Graft for Parkinson's Disease
Lexington, KentuckyThis phase I double-blind study focuses on the safety and feasibility of implanting autologous peripheral nerve tissue (PNT) into the substantia nigra area of the brain in persons who have been diagnosed with either Parkinson's disease (PD) or Multiple System Atrophy (MSA). 7 participants will be enrolled, with 4 participants receiving the graft and 3 receiving a sham surgery. Eligible participants will be early in their diagnosis with a lower burden of symptoms. Participants will be followed initially for one year after surgery.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:40 - 75
Sex:All
7 Participants Needed
ARCT-032 for Cystic Fibrosis
Northfield, IllinoisARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Recent Hemoptysis, Major Surgery, Transplant, Others
Must Not Be Taking:Systemic Corticosteroids
12 Participants Needed
Lu AF82422 for Multiple System Atrophy
Farmington Hills, MichiganThe main goal of this trial is to evaluate the efficacy and safety of Lu AF82422 for the treatment of participants with Multiple System Atrophy (MSA).
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:40 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Previous Lu AF82422, Other CNS Diseases, Others
360 Participants Needed
Daptomycin vs. Vancomycin for Staph Bacteremia
Montreal, QuebecThis is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.
This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Allergy, MRSA Pneumonia, Others
300 Participants Needed
Combination Vaccine for Flu and COVID-19
Valparaiso, IndianaThis study will evaluate the reactogenicity, safety, and immune response of Flu Seasonal/SARS-CoV-2 mRNA (mRNA Flu/COVID-19) combination vaccine. The flu portion will target multiple strains of the flu virus, while the COVID-19 part will focus on the spike protein of the SARS-CoV-2 virus. Both parts of this vaccine have been tested individually before. This will be the first study to test the combined vaccine in humans in healthy adult participants.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
780 Participants Needed
Rapcabtagene Autoleucel for Systemic Sclerosis
Chicago, IllinoisThe purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Pulmonary Hypertension, Renal Pathology, Hypertension, Others
86 Participants Needed
Palatal Expanders for Misaligned Teeth
Naperville, IllinoisThe purpose of this study is to compare expansion result and the overall experience between the Invisalign Palatal Expander and the Hyrax expander.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:6 - 11
Sex:All
Key Eligibility Criteria
Disqualifiers:Cleft Palate, Active Caries, Periodontal Disease, TMD, Others
36 Participants Needed
mRNA-1273.712 Vaccine for Healthy Subjects
Blue Ash, OhioThe primary objective of this study is to assess cardiac troponin I (cTnI) values in participants who received mRNA-1273.712 or placebo.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:12 - 30
Sex:All
1000 Participants Needed
mRNA-1403 for Stomach Flu
Columbus, OhioThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Chronic GI Disease, Immunodeficiency, Others
Must Not Be Taking:Immunosuppressants, Blood Products
25000 Participants Needed
mRNA Vaccine for Flu
Columbus, OhioThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against protocol-defined influenza-like illness (ILI) caused by any influenza A or B strains.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Malignancy, Anaphylaxis, Others
Must Not Be Taking:Corticosteroids, Immunosuppressants, Antivirals, Others
56000 Participants Needed
Mesalamine for Ulcerative Colitis
Cleveland, OhioThis trial is testing mesalamine capsules to see if they are safe and effective for children with Ulcerative Colitis. The medication helps reduce inflammation in the colon. About 80 children will take the capsules regularly for several months, and their health will be monitored through regular check-ups and tests. Mesalamine has been shown to be effective in maintaining remission in ulcerative colitis and is well-tolerated.
Pivotal Trial
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:5 - 17
Sex:All
80 Participants Needed
Phage Therapy for MDRO Decolonization
Philadelphia, PennsylvaniaThis is a randomized, open label, comparative Phase II trial being conducted to determine whether fecal microbiota transplant using Penn Microbiome Therapy (PMT) products helps standard therapy eradicate antibiotic-resistant bacteria.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Neutropenia, Pregnancy, Gastrointestinal Disease, Others
Must Be Taking:Antibiotics
150 Participants Needed
mRNA Vaccine for COVID-19 and Flu
River Forest, IllinoisThe purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:50 - 64
Sex:All
932 Participants Needed
mRNA Vaccine for Flu
Lexington, KentuckyThe purpose of this study is to assess the safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent vaccine (GSK4382276A) candidate against influenza, administered in healthy younger adults (YA) and older adults (OA).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 85
Sex:All
843 Participants Needed
Brain Stimulation for Mild Cognitive Impairment
Ann Arbor, MichiganThis study will evaluate the effects of a form of non-invasive brain stimulation on brain functioning and memory in cognitively intact older adults (healthy controls, HC) and in those with mild cognitive impairment (MCI).
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:60+
Sex:All
Key Eligibility Criteria
Disqualifiers:Neurological Conditions, Mental Illness, Sensory Impairments, Alcohol Or Drug Abuse, Others
80 Participants Needed
STX-001 + Keytruda for Solid Tumors
Pittsburgh, PennsylvaniaPhase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Organ Transplant, HIV, Others
Must Not Be Taking:Anticoagulants, Immunosuppressants
108 Participants Needed
COVID-19 Vaccine + RSV Vaccine for Adults 50+
Evansville, IndianaThis study will assess the immunogenicity, safety and reactogenicity of the RSVPreF3 OA investigational vaccine when it is co-administered with a COVID-19 messenger ribonucleic acid (mRNA) vaccine (Omicron XBB.1.5), compared to administration of the vaccines separately in adults aged 50 years and above.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:50+
Sex:All
842 Participants Needed
PP-007 for Ischemic Stroke
Toledo, OhioThis trial tests the safety of PP-007, a modified cow protein given through an IV, in stroke patients. It aims to improve blood flow and reduce brain damage. The study includes patients already receiving standard stroke treatments.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
24 Participants Needed
Swab Testing for Community-Acquired Pneumonia
Nashville, TennesseeThis trial tests if quickly informing doctors that a patient does not have MRSA can reduce the use of a strong antibiotic called vancomycin in critically ill adults with pneumonia. The goal is to avoid unnecessary antibiotic use and its serious side effects.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
277 Participants Needed
Combination Treatment for Staph Infections
Whiteriver, ArizonaIndigenous persons experience a high burden of Staphylococcus aureus (SA) invasive disease and skin and soft tissue infections. SA carriage on the skin is factor for development of SA infections. The goal of this clinical trial is to evaluate a community-informed approach to reduce carriage of SA. Participants will be assigned to education and household supplies for prevention of SA with and without a biomedical intervention. Researchers will compare SA carriage in the two groups.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Current SA Infection, Homelessness, Others
Must Not Be Taking:Antibiotics
120 Participants Needed
Rapid Testing for Bacterial Blood Infections
Nashville, TennesseeBacterial blood stream infections are common and life-threatening. Bloodstream infections have historically been identified using blood cultures, which often take 24-72 hours to result and are imperfectly sensitive. Early administration of antimicrobial therapy is a fundamental component of the management of adults presenting to the hospital with a suspected bloodstream infection and/or sepsis.
But because blood cultures frequently take 24-72 hours to result, patients are typically treated with empiric, broad spectrum antibiotics. In a meta-analysis of sepsis studies, empirical antibiotic therapy was inappropriate for the organism that ultimately grew in culture in almost half of patients. Thus, patients are commonly exposed to unnecessary antibiotics without evidence of infection or with evidence of infection requiring narrow antibiotic selection. For example, current guidelines recommend the use of empiric intravenous vancomycin as coverage for a bloodstream infection caused by the bacterial pathogen methicillin-resistant S. aureus (MRSA). Vancomycin requires careful monitoring due to its narrow therapeutic range and high risk of toxicity. Administration of vancomycin to patients who do not have MRSA can lead to avoidable adverse drug events and costs, as well as drive antimicrobial resistance.
There has been increasing interest in using rapid diagnostic tests that identify bacteria directly from whole blood samples without relying on growth in culture, referred to as "direct-from-blood" tests, to guide early therapeutic management of patients with suspected bloodstream infections in addition to standard blood cultures. One such FDA-approved, direct-from-blood test is the T2Bacteria® Panel. This panel's performance as a direct-from blood test for bacterial pathogens has been described in previous studies. A recent meta-analysis of largely observational studies reported a faster transition to targeted microbial therapy and de-escalation of empirical microbial therapy, as well as a shorter duration of intensive care unit stay and hospital stay for patients who received this direct-from-blood test.
We will conduct a pragmatic, randomized clinical trial examining the effect of using the T2Bacteria® Panel direct from-blood testing, compared to using blood cultures alone (standard of care), on antimicrobial receipt and clinical outcomes for adults presenting to the hospital with suspected infection and who have been initiated on empiric therapy with intravenous vancomycin.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
500 Participants Needed
mRNA VLP Vaccine for COVID-19
Chicago, IllinoisThis trial is testing two new vaccines, AZD9838 and AZD6563, in healthy adults to see if they are safe and help the immune system fight COVID-19.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 64
Sex:All
243 Participants Needed
mRNA-1345 Vaccine for Respiratory Syncytial Virus
Saginaw, MichiganThis trial is testing a new vaccine called mRNA-1345 that aims to protect against a lung infection virus known as RSV. The study focuses on pregnant women and their newborns. The vaccine works by teaching the body to recognize and fight the virus using a small piece of genetic material. mRNA-1345 is among the most promising RSV vaccines currently being tested.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 40
Sex:All
Key Eligibility Criteria
Disqualifiers:Anaphylaxis, Drug Abuse, Fever, Others
Must Not Be Taking:MRNA Vaccines
360 Participants Needed
mRNA Vaccine for Respiratory Syncytial Virus
Huber Heights, OhioThis trial is testing a new vaccine called mRNA-1345 to protect young children and high-risk older children from RSV. The vaccine works by teaching the immune system to recognize and fight the virus. mRNA-1345 is among the most promising RSV vaccines, leveraging the success of mRNA technology seen in COVID-19 vaccines.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:2 - 17
Sex:All
346 Participants Needed
mRNA-1345 Vaccine for RSV
Detroit, MichiganThis trial tests the safety and immune response of the mRNA-1345 vaccine in high-risk adults and those with organ transplants. The vaccine uses genetic instructions to help the body recognize and fight the virus.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
1150 Participants Needed
GDNF Gene Therapy for Multiple System Atrophy
Columbus, OhioThis trial is testing a new gene therapy for people with Multiple System Atrophy (MSA). The therapy uses a harmless virus to deliver a gene into the brain, which then produces a protein that helps protect brain cells. The goal is to see if this treatment is safe and if it can help slow down the progression of MSA.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:35 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Parkinson's, Dementia, Psychosis, Cancer, Others
Must Be Taking:Anti-parkinsonian
9 Participants Needed
ONO-2808 for Multiple System Atrophy
Columbus, OhioThis trial is testing a new drug called ONO-2808 in patients with Multiple System Atrophy (MSA). The study aims to see if the drug is safe, how it behaves in the body, and whether it can improve symptoms of MSA. Researchers are comparing three different doses of ONO-2808.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:30 - 80
Sex:All
92 Participants Needed
mRNA-1608 Vaccine for Genital Herpes
Beachwood, OhioThis trial is testing a new vaccine called mRNA-1608 in people who frequently get genital herpes. The vaccine aims to help their immune system recognize and fight the herpes virus, which could reduce how often and how severely they get outbreaks.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18 - 55
Sex:All
365 Participants Needed
Nicotinamide Riboside for Sarcopenia
Buffalo, New YorkFrailty is an age-associated clinical condition of poor physiological reserve that increases risks for falls, hospitalization and mortality. Nicotinamide adenine dinucleotide (NAD) is a critical co-factor needed for many cellular processes. The natural levels of NAD decline aging and this has been linked to physical performance decline in animals. Human trials have demonstrated that nicotinamide riboside (NR), a form of vitamin B3, is safe and effectively increases NAD+ levels. In animal studies, NR improves treadmill performance and muscle quality. Here the investigators propose a double-blind randomized control trial to assess the benefits of NR supplementation on human muscle function and physiology. The investigators anticipate the research findings will support the use of this nutritional supplement to improve the health of Veterans during aging.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:65 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Congestive Heart Failure, COPD, Others
144 Participants Needed
Page 1 of 2+
Frequently Asked Questions
How much do Mrsa clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Mrsa clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Mrsa trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Mrsa is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Mrsa medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Mrsa clinical trials ?
Most recently, we added mRNA-1083 Vaccine for Influenza and COVID-19, Sural Nerve Graft for Parkinson's Disease and ARCT-032 for Cystic Fibrosis to the Power online platform.